Physician profile
Larry K Midyett
NPI 1174555957
$210,126.08
in general payments reported to CMS, 2019-2025
31 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $22K · 2021: $45K · 2022: $3,800 · 2023: $32K · 2024: $34K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Travel and Lodging: $7,733 · Food and Beverage: $7,696 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,662.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,457.73 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,337.50 |
| Travel and Lodging | $7,732.60 |
| Food and Beverage | $7,696.24 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $195,394.20 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Tandem Diabetes Care, INC. | $9,558.59 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $1,064.38 | 2019-2025 | |
| Abbvie INC. | $860.25 | 2019-2024 | |
| Novo Nordisk INC | $645.63 | 2019-2024 | Sogroya, Ozempic, Rybelsus |
| Lilly USA, LLC | $469.09 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $282.59 | 2021-2024 | Omnipod |
| Dexcom, INC. | $269.62 | 2019-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $201.55 | 2019-2025 | |
| Antares Pharma, INC. | $200.22 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $162.69 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $123.76 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $116.41 | 2019-2023 | Bylvay |
| Corcept Therapeutics | $97.35 | 2023-2024 | Korlym |
| Ascendis Pharma Endocrinology INC | $80.66 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $70.34 | 2021-2024 | Supprelin |
| Ferring Pharmaceuticals INC. | $68.93 | 2019-2020 | |
| Cequr Corporation | $66.67 | 2023-2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $62.99 | 2020-2023 | Gvoke Hypopen |
| Tolmar Pharmaceuticals, INC. | $57.64 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $55.39 | 2022-2023 | Dupixent |
| Ibsa Pharma INC. | $33.83 | 2019 | |
| Azurity Pharmaceuticals, INC. | $29.33 | 2023-2024 | Triptodur, Triptodur |
| Medtronic, INC. | $26.37 | 2022-2023 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $23.01 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $19.95 | 2024 | |
| Endo USA, INC. | $19.83 | 2024 | Supprelin |
| Arbor Pharmaceuticals, INC. | $18.76 | 2022 | |
| Amgen INC. | $18.22 | 2024 | Tepezza |
| Aegerion Pharmaceuticals, INC. | $16.59 | 2019 | |
| Medtronic Minimed, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Midyett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.